✦ LIBER ✦

Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes

✍ Scribed by AJ Palmer; R Chen; WJ Valentine; S Roze; B Bregman; N Mehin; S Gabriel

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB33 COST-CONSEQUENCE ANALYSIS OF SCREE

✍ AJ Palmer; WJ Valentine; S Roze; R Chen; S Gabriel; B Bregman; N Mehin; HH Parvi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PDB40 COST-UTILITY ANALYSIS IN A USA SET

✍ AJ Palmer; R Chen; WJ Valentine; S Roze; S Gabriel; N Mehin; B Bregman; R Rodby 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Prevalence of nephropathy in Greek patie

✍ Aris D. Efstratopoulos; Sofia M. Voyaki; Athanasios Baltas; Sofia Siasiakou; Vas 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 45 KB

Cost Effectiveness Analysis of a Hyperte

✍ David Ly; Fu Z. Alex; Hebert Christopher 📂 Article 📅 2009 🏛 Le Jacq Communications, Inc. 🌐 English ⚖ 240 KB

PDB16 SELF MONITORING OF BLOOD GLUCOSE I

✍ AJ Palmer; ME Minshall; WJ Valentine; V Foos; SL Tunis 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

196: Cost-Effectiveness of Aliskiren as

✍ James L. Palmer; Veronica C. Munk; Robert W. Kotchie; Gabor Vincze; Alan Charney 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 184 KB